Averix Bio announces submission of drug master file for cannabidiol API (CBD) Isolate
Averix Bio announces its submission of a Drug Master File (DMF) to the US Food & Drug Administration (FDA) for cannabidiol (CBD) isolate.
Unlike most manufacturers, Averix ingredients are not synthetic but instead made from phytocannabinoid industrial hemp. The submission (DMF 036798) signifies Averix Bio’s commitment to bringing the highest quality ingredients to clinical trials and the pharmaceutical, cosmetics, nutraceutical and veterinary markets.
Wilson, North Carolina (February 22, 2022) - Averix Bio announces its submission of a Drug Master File (DMF) to the US Food & Drug Administration (FDA) for cannabidiol (CBD) isolate. Unlike most manufacturers, Averix ingredients are not synthetic but instead made from phytocannabinoid industrial hemp. The submission (DMF 036798) signifies Averix Bio’s commitment to bringing the highest quality ingredients to clinical trials and the pharmaceutical, cosmetics, nutraceutical and veterinary markets.
Averix Bio is a large-scale producer of pharmaceutical API cannabinoid ingredients for international markets. Averix Bio’s manufacturing facility complies with current good manufacturing practices (cGMP), meeting U.S. and international industry standards for pharmaceutical ingredient and product manufacturing, including 21 CFR Parts 210/211 compliance and ICH Q7. A manufacturer that is 200-level cGMP compliant will have strong quality management systems, rigorous operational testing, high-quality raw materials, and certified testing laboratories. Additionally, Averix Bio operates a detailed cultivation program, thereby ensuring its industrial hemp is locally grown, non-GMO, sustainably farmed and carefully tracked starting with soil and genetics.
'Averix Bio was built to be a tier one ingredient partner for pharmaceutical and other companies who want consistent, repeatable materials. Our strict processing and quality control departments ensures our partners de-risk their supply chain and work with a company committed to our motto – trackable, transparent and trustworthy. Unlike most companies, our materials actually starts with a cultivation program focused on soil and hemp genetics, ending up as active pharmaceutical ingredients (APIs). I could not be more proud of our team, the long hours pursuing a DMF filing, and the internal commitment to quality,' said Miles Wright, Chief Executive Officer at Averix Bio.
About Averix Bio
Averix Bio is a U.S.-based cannabinoid research and extraction company producing 21 CFR Part 210 and Part 211 and ICH Q7 compliant cGMP API phytocannabinoid ingredients. The company offers the highest-quality cannabinoid ingredients for use in the pharmaceutical, nutraceutical, food and beverage, cosmetic and veterinary sectors. Averix Bio ensures consistent quality from seed-to-shelf, forming the cornerstone of a corporate foundation built on traceability, transparency, and trust. Led by a world-class team with decades of cGMP and pharmaceutical experience, Averix Bio is on a mission to bring healthier cannabinoid-based medical solutions to patients around the world. For more information, email Miles Wright ([email protected]) or contact the company at +1 252-220-0887
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance